146 active not recruiting. 146 Phase 2, 26 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 146 | Active not recruiting 146 |
| Phase 1 | 26 | Active not recruiting 26 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma JNJ-79635322 - Multiple Myeloma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 168 | 2026-02-08 | 2026-11-03 |
| Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel Nivolumab - Multiple Myeloma | Phase 2 | Active not recruiting | Wake Forest University Health Sciences | 1 | 2025-02-28 | 2026-07-13 |
| MMRC Horizon One: RRMM (MMRC-099) Teclistamab Monotherapy, Teclistamab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Multiple Myeloma Research Consortium | 300 | 2024-11-17 | 2026-06-05 |
| A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma Cilta-cel, Talquetamab - Multiple Myeloma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 11 | 2024-09-16 | 2026-11-03 |
| GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma GR1803 injection - Multiple Myeloma | Phase 2 | Active not recruiting | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 116 | 2024-08-26 | 2026-05-27 |
| A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma Cilta-cel, Talquetamab, Daratumumab - Multiple Myeloma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 43 | 2024-08-20 | 2026-11-03 |
| Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant Belantamab Mafodotin, Lenalidomide - Plasma Cell Myeloma | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 4 | 2024-08-19 | 2026-10-16 |
| Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 58 | 2024-07-23 | 2026-09-25 |
| Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma Teclistamab, Talquetamab, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | Nantes University Hospital | 103 | 2024-06-26 | 2026-03-17 |
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma Linvoseltamab - Smoldering Multiple Myeloma (SMM) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 40 | 2024-01-30 | 2026-04-13 |
| Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma Teclistamab, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | University Hospital, Lille | 74 | 2023-12-21 | 2026-09-25 |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment Linvoseltamab - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 148 | 2023-12-19 | 2026-11-06 |
| Sequential Therapy in Multiple Myeloma Guided by MRD Assessments Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance - Multiple Myeloma | Phase 2 | Active not recruiting | University of Alabama at Birmingham | 300 | 2023-12-13 | 2026-09-22 |
| Isa-Pom-Dex in Elderly/Frail Subjects With RRMM Isatuximab, Pomalidomide, Dexamethasone - Multiple Myeloma, Relapse | Phase 2 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 6 | 2023-12-05 | 2026-06-09 |
| Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes Elranatamab (PF-06863135) - Multiple Myeloma in Relapse | Phase 2 | Active not recruiting | PETHEMA Foundation | 50 | 2023-11-23 | 2026-06-04 |
| Cevostamab Following CAR T Cell Therapy for RRMM Cevostamab - Relapsed/Refractory Multiple Myeloma | Phase 2 | Active not recruiting | University of Pennsylvania | 30 | 2023-07-11 | 2025-12-18 |
| Elimination of Minimal Residual Disease After Transplant Dexamethasone, Isatuximab, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | Medical College of Wisconsin | 30 | 2023-06-26 | 2026-10-20 |
| A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia anti-BCMA CAR-T, VRD-based Regimen - Plasma Cell Leukemia | Phase 2 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 25 | 2023-05-23 | 2026-11-04 |
| A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities anti-BCMA CAR-T, VRD-based Regimen - Multiple Myeloma | Phase 2 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2023-04-21 | 2026-06-03 |
| CAR- PRISM (PRecision Intervention Smoldering Myeloma) Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2023-04-19 | 2026-03-12 |
Showing 20 of 146. Sign in to see all of them.
Lymphoma (34) · Hematologic Neoplasms (18) · Recurrence (9) · Lymphoma, Non-Hodgkin (7) · Neoplasms, Plasma Cell (6) · Hodgkin Disease (5) · Myelodysplastic Syndromes (5) · Neoplasms (4) · Anemia, Aplastic (3) · Leukemia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myeloid, Acute (3) · Lymphoma, Mantle-Cell (3)
Hemic and Lymphatic Diseases (146) · Immune System Diseases (146) · Neoplasms by Histologic Type (146) · Cardiovascular Diseases (145) · Hemorrhagic Disorders (145) · Hemostatic Disorders (145) · Immunoproliferative Disorders (145) · Vascular Diseases (145) · Blood Protein Disorders (144) · Hematologic Diseases (144) · Lymphoproliferative Disorders (144) · Paraproteinemias (144) · Neoplasms (142) · Neoplasms, Plasma Cell (140) · Lymphatic Diseases (38)
Dexamethasone (62) · Lenalidomide (38) · daratumumab (36) · Bortezomib (24) · carfilzomib (24) · Calcium Dobesilate (23) · Biopsy (18) · Specimen Handling (17) · Magnetic Resonance Spectroscopy (15) · isatuximab (15) · pomalidomide (15) · Cyclophosphamide (12) · belantamab mafodotin (11) · auricularum (9) · dexamethasone 21-phosphate (9)
National Cancer Institute (NCI) (32) · Memorial Sloan Kettering Cancer Center (10) · GlaxoSmithKline (6) · Janssen Research & Development, LLC (5) · M.D. Anderson Cancer Center (5) · PETHEMA Foundation (5) · Nantes University Hospital (4) · AbbVie (3) · City of Hope Medical Center (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · Mayo Clinic (3) · Celgene (2) · Dana-Farber Cancer Institute (2) · Massachusetts General Hospital (2) · Medical College of Wisconsin (2)
United States (112) · France (19) · Spain (19) · Germany (13) · Australia (12) · Canada (12) · Greece (11) · Italy (9) · Brazil (7) · Israel (7) · Netherlands (7) · South Korea (7) · China (6) · Norway (6) · Sweden (6)
David S Hong (3) · Filip Janku (3) · Andrew J Yee, MD (2) · Gunjan Shah, MD (2) · Jason J Luke (2) · John L Hays (2) · Kevin M Kalinsky (2) · Omar Nadeem, MD (2) · Aaron S Mansfield (1) · Adam D Cohen, MD (1)
PMID 33357481, PMID 34182226, PMID 35285981, PMID 20385792, PMID 25824111, PMID 26586415, PMID 29567784, PMID 32463741, PMID 33048619, PMID 33682447, PMID 33730360, PMID 34048681, PMID 34388020, PMID 34470049, PMID 34732857, PMID 34826409, PMID 35027656, PMID 35133871, PMID 35138919, PMID 36029527, PMID 36095849, PMID 36209764, PMID 36351402, PMID 36529145, PMID 37053535, PMID 37173224, PMID 37322121, PMID 37611156, PMID 37753960, PMID 37934000, PMID 37945755, PMID 38270219, PMID 38394666, PMID 38591867, PMID 38677302, PMID 38776914, PMID 39345094, PMID 39388024, PMID 39576965, PMID 39626297, PMID 39666929, PMID 39693587, PMID 39778168, PMID 39913886, PMID 40153687, PMID 40501401, PMID 40865033, PMID 41066729, PMID 41346230, PMID 41358582
U10CA180820 (30), U24CA196172 (17), 2023 (16), 2019 (5), P30CA033572 (2), 2014 (1), 2016 (1), 2017 (1), 2018 (1), 2025 (1), P30CA014089 (1), P30CA015083 (1), P30CA138292 (1), P50CA186781 (1), UM1CA186689 (1)